The researchers found nearly half (47%) of the posts focused on efficacy, while 16% discussed adverse effects such as acne, ...

An investigational oral Janus kinase (JAK) inhibitor failed to meet most primary endpoints in a phase III trial of patients ...

Deuruxolitinib showed significant efficacy and safety in hair regrowth stimulation among adult patients with alopecia areata, ...

Giant cell arteritis (GCA) can be successfully treated with the oral Janus kinase (JAK) inhibitor upadacitinib (Rinvoq), ...

Fedratinib can reduce symptoms and spleen volume in patients with myelodysplastic syndrome (MDS) or myeloproliferative neoplasms (MPNs), according to research presented at the ASH Annual Meeting 2024.

The 48-week end points of the MANIFEST-2 study show improvements in spleen reduction, symptoms, bone marrow fibrosis, and ...

Six of ten (60%) patients experienced a ≥50% reduction in TSS at week 24. The best response of SVR in 2 of 8 patients (JAK inhibitors-treated) was -41.2% and -34.9%, respectively. At week 24, 3 of 6 ...

JAK inhibitors like baricitinib, ritlecitinib, and brepocitinib show promise in treating alopecia areata, with baricitinib approved by FDA and EMA. Baricitinib significantly reduced SALT scores at ...

Geron (GERN) announced results from an oral presentation at the 66th American Society of Hematology, or ASH, annual meeting, reporting Phase 1 ...

LEO Pharma has announced that its Anzupgo (delgocitinib) cream has been approved by the Medicines and Healthcare Products ...